Stem Cell Therapeutics Corp. Announces Presentation of Modified REGENESIS Trial Results at the International Stroke Meeting
February 09 2011 - 6:00PM
Marketwired
Stem Cell Therapeutics Corp. ("SCT" or the "Company") (TSX VENTURE:
SSS) is pleased to announce that Dr. Steven Cramer of the
University of California at Irvine will be presenting results from
the REGENESIS-LED trial at the International Stroke Conference,
today in Los Angeles, California.
The title of the poster presentation is entitled, "Study of
NTx®-265: Human Chorionic Gonadotropin (hCG) and Epoetin Alfa (EPO)
in Acute Ischemic Stroke Patients (REGENESIS Trial)."
"This presentation represents an important opportunity to review
and discuss the modified REGENESIS trial for the first time with
the stroke community." said Dr. Allen Davidoff, Chief Scientific
Officer of SCT. "SCT looks forward to discussions of this trial at
the meeting and integrating those discussions into our ongoing
strategic planning for the NTx®-265 program in Acute Ischemic
Stroke".
About Stem Cell Therapeutics Corp: Stem Cell Therapeutics Corp.
is a Canadian public biotechnology company (TSX VENTURE: SSS)
focused on the development and commercialization of drug-based
therapies to treat central nervous system diseases. SCT is a leader
in the development of therapies that utilize drugs to stimulate a
patient's own resident stem cells. The Company's programs aim to
repair neurological function lost due to disease or injury. SCT's
extensive patent portfolio of owned and licensed intellectual
property supports the potential expansion into future clinical
programs in numerous neurological diseases such as traumatic brain
injury, multiple sclerosis, Huntington's disease, Alzheimer's
disease, and ALS.
For further information on Stem Cell Therapeutics Corp., visit
www.stemcellthera.com.
These securities have not been registered under the United
States Securities Act of 1933, as amended, or the securities laws
of any state, and may not be offered or sold within the United
States or to, or for the account or benefit of U.S. persons unless
an applicable exemption from U.S. registration requirements is
available.
Except for historical information, this press release may
contain forward-looking statements, which reflect the Company's
current expectation regarding future events. These forward-looking
statements involve risk and uncertainties, which may cause but are
not limited to, changing market conditions, the successful and
timely completion of clinical studies, the establishment of
corporate alliances, the impact of competitive products and
pricing, new product development, uncertainties related to the
regulatory approval process and other risks detailed from time to
time in the Company's ongoing quarterly and annual reporting.
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Contacts: Stem Cell Therapeutics Corp. Allen Davidoff, PhD Chief
Scientific Officer 403-245-5495 ext.226 adavidoff@stemcellthera.com
Stem Cell Therapeutics Corp. Angelika Goncalves DaSilva Operations
Manager 403-245-5495 ext. 221 adasilva@stemcellthera.com
www.stemcellthera.com
Sunvest Minerals Corp (TSXV:SSS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Sunvest Minerals Corp (TSXV:SSS)
Historical Stock Chart
From Jul 2023 to Jul 2024